Treatment with HDACi targeting HDAC1-3 downregulates FLIP expression predominantly via post-transcriptional mechanisms, and results in death receptor- and caspase-8-dependent apoptosis in NSCLC cells, but not in normal lung cells (Riley et al., 2013). Here, CASP8 is linked to non-small cell lung carcinoma.